Join us to discuss this extension of the TUMORAPA trial - in a joint session with the #DermJC. Should kidney transplant recipients with squamous cell cancer be switched to sirolimus?
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles